3,886 Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) Acquired by Allianz SE

Allianz SE purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 3,886 shares of the medical equipment provider’s stock, valued at approximately $346,000.

Several other hedge funds have also recently bought and sold shares of the stock. Janus Henderson Group PLC grew its stake in Lantheus by 7.7% during the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock worth $393,844,000 after buying an additional 257,022 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Lantheus by 2.0% in the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after purchasing an additional 32,551 shares in the last quarter. Reinhart Partners LLC. raised its position in Lantheus by 9.9% in the 4th quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider’s stock worth $122,280,000 after purchasing an additional 123,282 shares during the last quarter. Swedbank AB lifted its holdings in Lantheus by 53.3% during the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock worth $99,054,000 after buying an additional 385,000 shares in the last quarter. Finally, Portolan Capital Management LLC increased its position in Lantheus by 6.1% in the third quarter. Portolan Capital Management LLC now owns 670,881 shares of the medical equipment provider’s stock worth $73,629,000 after purchasing an additional 38,776 shares during the period. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on LNTH shares. The Goldman Sachs Group started coverage on shares of Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target for the company. B. Riley lowered their price target on Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a research note on Friday, March 21st. JMP Securities reissued a “market outperform” rating and set a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. Finally, Truist Financial upped their target price on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Lantheus presently has a consensus rating of “Moderate Buy” and an average price target of $129.43.

Insider Buying and Selling

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the sale, the director now directly owns 440,399 shares of the company’s stock, valued at $41,551,645.65. The trade was a 10.76 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director James H. Thrall sold 1,000 shares of the stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 64,109 shares of company stock worth $6,110,806. 1.50% of the stock is owned by insiders.

Lantheus Stock Down 0.9 %

Shares of LNTH stock opened at $96.16 on Monday. The company has a market capitalization of $6.59 billion, a price-to-earnings ratio of 16.00 and a beta of 0.38. Lantheus Holdings, Inc. has a 12-month low of $58.16 and a 12-month high of $126.89. The firm has a fifty day moving average of $93.21 and a 200-day moving average of $96.38.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. On average, equities analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.